Exelixis Inc (NASDAQ: EXEL) started the day on Thursday, with a price decrease of -0.69% at $44.5, before settling in for the price of $44.81 at the close. Taking a more long-term approach, EXEL posted a 52-week range of $31.90-$49.62.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 11.55%. Meanwhile, its Annual Earning per share during the time was 11.55%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 67.47%. This publicly-traded company’s shares outstanding now amounts to $268.10 million, simultaneously with a float of $258.89 million. The organization now has a market capitalization sitting at $11.93 billion.
Exelixis Inc (EXEL) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Exelixis Inc’s current insider ownership accounts for 3.44%, in contrast to 94.29% institutional ownership. Preceding that transaction, on Nov 25 ’25, Company’s Director bought 27,532 for 43.12, making the whole transaction’s value amount to 1,187,235. This particular insider is now the holder of 1,553,262 in total.
Exelixis Inc (EXEL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.73 per share during the current fiscal year.
Exelixis Inc’s EPS increase for this current 12-month fiscal period is 67.47% and is forecasted to reach 3.36 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 34.74% through the next 5 years, which can be compared against the 11.55% growth it accomplished over the previous five years trading on the market.
Exelixis Inc (NASDAQ: EXEL) Trading Performance Indicators
Let’s observe the current performance indicators for Exelixis Inc (EXEL). It’s Quick Ratio in the last reported quarter now stands at 3.68. Alongside those numbers, its PE Ratio stands at $18.73, and its Beta score is 0.42. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.21. Similarly, its price to free cash flow for trailing twelve months is now 15.30.
In the same vein, EXEL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 2.38, a figure that is expected to reach 0.82 in the next quarter, and analysts are predicting that it will be 3.36 at the market close of one year from today.
